The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.119.5.432

1. One hundred and eighty voluntary inpatients (102 schizophrenic subjects, 67 subjects with affective disorders, and 11 "other" diagnoses) were studied during treatment with imipramine.

2. Seven imipramine induced behavioral reaction patterns and their relationships to diagnosis, age, sex, patterns of medication use, and hospital discharge evaluation are presented. These include mood elevation, explicit verbal denial, manic, reduction of episodic anxiety, agitated disorganization, anhedonic socialization, and non-response.

3. Imipramine was favorably evaluated in 79% of subjects with affective disorders and 51% of schizophrenic patients.

4. The use of psychiatric reaction patterns to psychotropic drugs for categorizing patients and providing a basis for a more rational pharmacotherapy are emphasized.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.